FDA Limits On Vasopressin Compounding Valid, Says Judge

Law360 (August 1, 2019, 6:24 PM EDT) -- A D.C. federal judge on Thursday chucked a challenge to the U.S. Food and Drug Administration's limits on drug compounding with the hormone vasopressin, rejecting assertions that the agency is improperly policing the practice of medicine.

U.S. District Judge Amit P. Mehta handed summary judgment to the FDA, which has insisted that it properly booted vasopressin from a list of active ingredients, which are known in the compounding world as bulk drug substances. Substances on that list are exempt from the agency's drug approval process.

In Thursday's ruling, Judge Mehta said that the FDA wasn't regulating the practice of medicine, as...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!